Cargando…

Thymoquinone, as a Novel Therapeutic Candidate of Cancers

To date, natural products are widely used as pharmaceutical agents for many human diseases and cancers. One of the most popular natural products that have been studied for anticancer properties is thymoquinone (TQ). As a bioactive compound of Nigella sativa, TQ has shown anticancer activities throug...

Descripción completa

Detalles Bibliográficos
Autores principales: Almajali, Belal, Al-Jamal, Hamid Ali Nagi, Taib, Wan Rohani Wan, Ismail, Imilia, Johan, Muhammad Farid, Doolaanea, Abd Almonem, Ibrahim, Wisam Nabeel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074212/
https://www.ncbi.nlm.nih.gov/pubmed/33923474
http://dx.doi.org/10.3390/ph14040369
_version_ 1783684303927902208
author Almajali, Belal
Al-Jamal, Hamid Ali Nagi
Taib, Wan Rohani Wan
Ismail, Imilia
Johan, Muhammad Farid
Doolaanea, Abd Almonem
Ibrahim, Wisam Nabeel
author_facet Almajali, Belal
Al-Jamal, Hamid Ali Nagi
Taib, Wan Rohani Wan
Ismail, Imilia
Johan, Muhammad Farid
Doolaanea, Abd Almonem
Ibrahim, Wisam Nabeel
author_sort Almajali, Belal
collection PubMed
description To date, natural products are widely used as pharmaceutical agents for many human diseases and cancers. One of the most popular natural products that have been studied for anticancer properties is thymoquinone (TQ). As a bioactive compound of Nigella sativa, TQ has shown anticancer activities through the inhibition of cell proliferation, migration, and invasion. The anticancer efficacy of TQ is being investigated in several human cancers such as pancreatic cancer, breast cancer, colon cancer, hepatic cancer, cervical cancer, and leukemia. Even though TQ induces apoptosis by regulating the expression of pro- apoptotic and anti-apoptotic genes in many cancers, the TQ effect mechanism on such cancers is not yet fully understood. Therefore, the present review has highlighted the TQ effect mechanisms on several signaling pathways and expression of tumor suppressor genes (TSG). Data from relevant published experimental articles on TQ from 2015 to June 2020 were selected by using Google Scholar and PubMed search engines. The present study investigated the effectiveness of TQ alone or in combination with other anticancer therapeutic agents, such as tyrosine kinase inhibitors on cancers, as a future anticancer therapy nominee by using nanotechnology.
format Online
Article
Text
id pubmed-8074212
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80742122021-04-27 Thymoquinone, as a Novel Therapeutic Candidate of Cancers Almajali, Belal Al-Jamal, Hamid Ali Nagi Taib, Wan Rohani Wan Ismail, Imilia Johan, Muhammad Farid Doolaanea, Abd Almonem Ibrahim, Wisam Nabeel Pharmaceuticals (Basel) Review To date, natural products are widely used as pharmaceutical agents for many human diseases and cancers. One of the most popular natural products that have been studied for anticancer properties is thymoquinone (TQ). As a bioactive compound of Nigella sativa, TQ has shown anticancer activities through the inhibition of cell proliferation, migration, and invasion. The anticancer efficacy of TQ is being investigated in several human cancers such as pancreatic cancer, breast cancer, colon cancer, hepatic cancer, cervical cancer, and leukemia. Even though TQ induces apoptosis by regulating the expression of pro- apoptotic and anti-apoptotic genes in many cancers, the TQ effect mechanism on such cancers is not yet fully understood. Therefore, the present review has highlighted the TQ effect mechanisms on several signaling pathways and expression of tumor suppressor genes (TSG). Data from relevant published experimental articles on TQ from 2015 to June 2020 were selected by using Google Scholar and PubMed search engines. The present study investigated the effectiveness of TQ alone or in combination with other anticancer therapeutic agents, such as tyrosine kinase inhibitors on cancers, as a future anticancer therapy nominee by using nanotechnology. MDPI 2021-04-16 /pmc/articles/PMC8074212/ /pubmed/33923474 http://dx.doi.org/10.3390/ph14040369 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Almajali, Belal
Al-Jamal, Hamid Ali Nagi
Taib, Wan Rohani Wan
Ismail, Imilia
Johan, Muhammad Farid
Doolaanea, Abd Almonem
Ibrahim, Wisam Nabeel
Thymoquinone, as a Novel Therapeutic Candidate of Cancers
title Thymoquinone, as a Novel Therapeutic Candidate of Cancers
title_full Thymoquinone, as a Novel Therapeutic Candidate of Cancers
title_fullStr Thymoquinone, as a Novel Therapeutic Candidate of Cancers
title_full_unstemmed Thymoquinone, as a Novel Therapeutic Candidate of Cancers
title_short Thymoquinone, as a Novel Therapeutic Candidate of Cancers
title_sort thymoquinone, as a novel therapeutic candidate of cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074212/
https://www.ncbi.nlm.nih.gov/pubmed/33923474
http://dx.doi.org/10.3390/ph14040369
work_keys_str_mv AT almajalibelal thymoquinoneasanoveltherapeuticcandidateofcancers
AT aljamalhamidalinagi thymoquinoneasanoveltherapeuticcandidateofcancers
AT taibwanrohaniwan thymoquinoneasanoveltherapeuticcandidateofcancers
AT ismailimilia thymoquinoneasanoveltherapeuticcandidateofcancers
AT johanmuhammadfarid thymoquinoneasanoveltherapeuticcandidateofcancers
AT doolaaneaabdalmonem thymoquinoneasanoveltherapeuticcandidateofcancers
AT ibrahimwisamnabeel thymoquinoneasanoveltherapeuticcandidateofcancers